Home / Market News / $CARL

$CARL news and market catalysts

The 6 most recent market catalysts affecting $CARL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 0 high impact 3 bullish 1 bearish Healthcare
Oct 12, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24
BTIG analyst Ryan Zimmerman maintained a 'Buy' rating on Carlsmed and modestly increased the price target from $23 to $24. This action signals ongoing analyst conviction in the com…
Sep 28, 2026 Corporate Catalyst Neutral Impact 55
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target
BTIG analyst Ryan Zimmerman reiterated a 'Buy' rating and maintained a $23 price target for Carlsmed (CARL). This action signals continued confidence from a prominent investment ba…
Sep 28, 2026 Corporate Catalyst Bearish Impact 55
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (CARL) filed an 8-K to affirm its fiscal year 2026 sales guidance, which remains in the range of $74.000 million to $78.000 million. This is a routine disclosure, as the c…
Sep 28, 2026 Corporate Catalyst Neutral Impact 75
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed announced the appointment of Richard Heppenstall as its new Chief Financial Officer, effective immediately, succeeding Leo Greenstein. This is a significant executive chan…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20
Truist Securities analyst Richard Newitter maintained a 'Buy' rating on Carlsmed (CARL) and raised the price target from $18 to $20. This action signals a positive outlook from a r…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M Est
Carlsmed (CARL) has filed an 8-K to announce an upward revision to its FY2026 sales guidance. The company's new outlook is $74.000 million-$78.000 million, up from the previous $72…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.